Ex vivo expansion of human hematopoietic progenitors and cells to support high-dose chemoradiation therapy: Five years of clinical experience

Cytokines, Cellular and Molecular Therapy

Volumn 6, Issue 2, 2000, Pages 97-108

  Chabannon, C ^a   Olivero, S ^a   Blaise, D ^a   Maraninchi, D ^a   Viens, P ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Bone marrow transplantation; Cell culture; Cord blood; Hematopoietic stem cells; Tissue engineering

Indexed keywords

ANTINEOPLASTIC AGENT;

BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ACTIVATION; CELL CULTURE; CLINICAL TRIAL; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; STEM CELL; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

EID: 0033698586     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: 10.1080/13684730050515822     Document Type: Review

References (166)

1. Filgrastim (r-metHuG-CSF): The first 10 years
2. The biology and clinical uses of blood stem cells
3. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marow transplantation in lymphoma patients
4. Peripheral blood stem cells and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs
5. Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT)
6. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukemia: Fist results of a randomised multicentre trial of the European Group of Blood and Marrow Transplantation
7. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation: A report from the Societe Francaise de Greffe de Moelle
8. Ex-vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage
9. Ex vivo expansion of enriched peripheral blood CD34+ positive progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma and erythropoietin
10. Optimization of culture conditions for ex vivo expansion of CD34+ cells from patients with stage 1V breast cancer
11. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
12. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation
13. Engraftment of gene modified umbilical cord blood cells in neonates with adenosine deaminase deficiency
14. Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vitro
15. Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures
16. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
17. Gene therapy of human severe combine immunodeficiency (SCID)-X1 disease
18. Ex-vivo expansion of hematopoietic precursors, progenitors and stem cells: The next generation of cellular therapeutics
19. Ex vivo expansion of hematopoietic progenitor cells for clinical use
20. Progress in the development of systems for in vitro expansion of human hematopoietic stem cells
21. Ex vivo expansion of hematopoietic stem and progenitor cells: Are we there yet?
22. Meeting report on an NHLBI workshop on ex vivo expansion of stem cells, July 29, 1999, Washington, D.C. National Heart Lung and Blood Institute
23. Presence of hematopoietic stem cells in the adult liver
24. Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo
25. Hematopoietic potential of stem cells isolated from murine skeletal muscle Proc Natl Acad Sci USA
26. The composition of CD34 subpopulations differs between bone marrow, blood and cord blood
27. A functional comparison of CD34+CD38- cells in cord blood and bone marrow
28. Comparison of the phenotype and clonogenicity of normal CD34+ cells from umbilical cord blood, granulocyte colony stimulating factor-mobilized peripheral blood, and adult bone marrow
29. Evaluation of ex vivo expansion potential of cord blood and bone marrow hematopoietic progenitor cells using cell tracking and limiting dilution analysis
30. Genetically modified CD34++ CD38- Lin- fetal liver progenitors reconstitute the SCID-hu mouse and express the transgene in T, B, myeloerythroid and progenitor cells
31. Ex vivo manipulations alter the reconstitution potential of mobilized human CD34+ peripheral blood progenitors
32. Unique differentiation programs of human fetal liver stem cells shown both in vitro and in vivo in NOD/SCID mice
33. Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow
34. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo
35. Selection and expansion of peripheral blood CD34+ cell in autologous stem cell transplantation for breast cancer
36. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity
37. CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens
38. Megakaryocyte progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients
39. The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation
40. Conditions controlling the proliferation of hematopoietic stem cells in vitro
41. Long-term culture of human bone marrow cells
42. A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38-progenitor cells in long-term cultures and semi-solid assays
43. Murine stromal cells counteract the loss of long-term culture-initiating cell potential induced by cytokines in CD34(+)CD38(low/neg) human bone marrow cells
44. Long-term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells
45. Murine stromal cell line HESS-5 maintains reconstituting ability of ex vivo-generated hematopoietic stem cells from human bone marrow and cytokine-mobilized peripheral blood
46. Mechanisms that regulate the cell cycle of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer
47. Ex vivo expansion of genetically marked Rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability
48. Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study
49. Ex vivo expansion of bone marroe progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer
50. Production of ex vivo expanded hematopoietic clls and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer, and receiving high doses of cyclophosphamide
51. Ex vivo expansion of autologous bone marrow CD34(+) cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons
52. Bone marrow repopulation by human marrow stem cells after long-term expansion culture on a porcine endothelial cell line
53. In vitro expansion of human peripheral blood CD34+ cells
54. The effects of Flk2/flt3 ligand as compared with c-kit ligand on short-term and long-term proliferation of CD34+ hematopoietic progenitors elicited from human fetal liver, umbilical cord blood, bone marrow, and mobilized peripheral blood
55. Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow
56. Flt-3 ligand is more potent than c-kit ligand for the synergistic stimulation of ex vivo hematopoietic cell expansion
57. Extensive amplification and self-renewal of human primitive hematopoeitic stem cells from cord blood
58. Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation
59. Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin
60. Ex vivo expansion of hematopoietic stem and progenitor cells - Robbing Peter to pay Paul
61. 1 or Rb oligonucleotides
62. Non cycling state of peripheral blood progenitor cells mobilized by granulocyte colony stimulating factor and other cyrokines
63. Functional isolation and characterization of human hematopoietic stem cells
64. +/CD38(hi) human marrow cells after in vitro cytokine exposure
65. A neutralizing anti-TGFb1 antibody promotes proliferation of CD34+Thy-1 peripheral blood progenitors and increases the number of transduced progenitors
66. Cell cycle distribution of cord blood-derived haematopoietic progenitor cells and their recruitment into the S-phase of the cell cycle
67. Cell-cycle related changes in repopulating capacity of human, mobilized peripheral blood CD34+ cells in non-obese diabetic/severe combined immune-deficient mice
68. FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex-vivo retroviral-mediated transduction
69. Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow
70. Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34(+) cells
71. Ex vivo expansion of mature human neutrophils with normal functions from purified peripheral blood CD34+ haematopoietic progenitor cells
72. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor
73. Gp130-signaling synergizes with FL and TPO for the long-term expansion of cord blood progenitors
74. Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: Novel responses to Flt-3 ligand and thrombopoietin
75. Cytokine manipulation of primitive human hematopoietic cell self-renewal
76. Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-1+Lin-cells with preserved ability to engraft SCID-hu bone
77. Long-term reconstitution of mice after ex vivo expansion of bone marrow cells: Differential activity of cultured bone marrow and enriched stem cell populations
78. Restrictions in the stem cell function of murine bone marrow grafts after ex vivo expansion of short term repopulating progenitors
79. Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer
80. A phase I trial of augmentation of unrelated umbilicalcord blood transplantation with ex-vivo expanded cells
81. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia
82. Ex vivo expanded mobilized peripheral blood CD34+ cells accelerate haematological recovery in a baboon model of autologous transplantation
83. Abrogation of post myeloablatire chemotherapy neutropenia by ex vivo expanded autologous CD34 cells
84. Transplantation of ex vivo expanded PBPC after high-dose chemotherapy results in decreased neutropenia
85. Transplantation of cancer patients receiving high-dose chemotherapy with ex vivo expanded cord blood cells
86. Drug therapy thrombopoietin
87. Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34(+) cells with stem cell facton and promegapoietin
88. A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for transfusion purposes
89. Development of antibodies to fetal calf serum with Arthus like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusion
90. Amplification of Sca1+ Lin- WGA+ cells in serum-free cultures containing steel factor, interleukin-6, and erythropoietin with maintenance of cells with long-term in vivo reconstituting potential
91. Tavassoli M, Hardy CL, Molecular basis of homing of intravenously transplanted stem cells to the marrow
92. Hematopoietic stem/progenitor cell mobilization A continuing quest for etiologic mechanisms
93. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of α4β1 integrin expression function
94. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow
95. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4
96. Transendothelial migration of CD34+ and mature hematopdietic cells: An in vitro study using a human bone marrow endothelial cell line
97. The chemokine receptor CXCR-4 is expresses on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1
98. Cytokines increase human hematopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins
99. Adhesion receptor expression by hematopoietic cell lines and murine progenitors: Modulation by cytokines and cell cycle status
100. Purification and characterization of mouse hematopoietic stem cells
101. Rapid and sustained hematopoietic recovery of lethally irradiated mice transplanted with purified hematopoietic stem cells
102. The early phase of engraftment after murine blood cell transplantation is mediated by hematopoietic stem cells
103. High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts
104. Sequential analysis of early hematopoietic reconstitution following allogeneic bone marrow transplantation with fluorescence in situ hybridization (FISH)
105. Detection of mixed chimerism and leukemic relapse after allogeneic bone marrow transplantation in subpopulations of leucocytes by fluorescent in situ hybridization in combination with the simultaneous immunophenotypic analysis of interphase cells
106. Early establishment of chimerism in the B and T lymphoid lineages after transplantation of allogeneic mobilized blood cells in patients with leukemia
107. Engraftment of MDR1 and NeoR gone-transduced hematopoietic cells after breast cancer chemotherapy
108. Collection, tumor contamination, and engraftment kinetic of highly purified hematopoietic progenitor cells to support high-dose therapy in multiple myeloma
109. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to postrransplant hematopoieric recovery following intensive systemic therapy
110. CFU-GM content of bone marrow grafts correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow
111. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment
112. Factors that influence collection and engraftment of autologous peripheral blood stem cells
113. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
114. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy
115. Autologous transplantation of blood stem cells mobilized with G-CSF alone on 93 patients with malignancies: The number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery
116. Does the granulocyte-macrophage colony-forming unit content in ex vivo expanded grafts predict the recovery of the recipient leukocytes?
117. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro
118. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay
119. Long-term human hematopoiesis in the SCID-hu mouse
120. Human stem cell assays in immune-deficient mice
121. Immunodeficient mice as models of human hematopoietic stem cell engraftment
122. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCD mice
123. Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: Analysis of gene transduction of long-lived progenitors
124. Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells
125. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy
126. Engraftment of SCID mice by human bone marrow hematopoietic cells cultured in vitro: An in vivo model for human gene transfer
127. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture
128. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: Evidence for the amplification and self-renewal of repopulating stem cells
129. Engraftmnt of cultured human hematopoietic cells in sheep
130. Accelerated recovery of peripheral blood cell counts in mice transplanted with in-vitro cytokine-expanded hematopoietic progenitors
131. Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential
132. Accelerated and long-term hematopoietic engraftment in mice transplanted with ex vivo expanded bone marrow
133. Partially differentiated ex vivo expanded cells accelerate hematologic recovery in myeloablated mice transplanted with highly enriched long-term repopulating stem cells
134. Mock retroviral infection alters developmental potential of murine bone marrow stem cells
135. Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts
136. Large scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion cultures
137. Long-term culture-initiating cell expansion is dependent on frequent medium exchanged combined with stromal and other accessory cell effects
138. A new 'two-step' procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation
139. Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor
140. Effects of prior therapy on in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells
141. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an HLA-identical sibling
142. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients
143. Outcome of cod-blood transplantation from related or unrelated donors
144. Outcomes among 562 recipients of placental-blood transplants from unrelated donors
145. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord - Cord Blood Transplant Group
146. Transplantation of allogeneic CD34+ blood cells
147. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy
148. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood
149. Allogeneic transplantation of selected CD34+ cells from peripheral blood: Experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT
150. Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD
151. Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin-3 and granulocyte-macrophage colony stimulating factor
152. Successful engraftment of T-cell-depleted haploidentical three-loci incompatible transplants in leukemia patient by adition of recombinant human granulocyte colony stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum
153. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
154. Gene-making to trace origin of relapse after autologous bone marrow transplantation
155. Genetic marking shows that Ph+ cells present in autologous transplants of chronic mydogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
156. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cells collections from breast cancer patients
157. Ex vivo expansion of CD34+ peripheral blood progenitor cells: Implications for the expansion of contaminating epihelial tumor cells
158. Fate of contaminating t(14;18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells
159. Ex vivo expansion of bone marrow from breast cancer patients: Reduction in tumor cell content through passive purging
160. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral blood progenitors and growth factors on engraftment
161. Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patient with breast cancer
162. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: A randomized multicenter study
163. A prospective randomized trial of buffy-coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high dose chemotherapy
164. Developmental potential and dynamic behavior of hematopoietic stem cells
165. Clonal and systemic analysis of long-term hematopoiesis in the mouse
166. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice